High-Purity CSF-1R Inhibitor Composition for Selective Targeting
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current CSF-1R inhibitors face issues such as off-target toxicity, plasma level increases of CSF-1, and impurities that affect stability and efficacy in pharmaceutical compositions, limiting their utility in treating conditions like solid tumors and tenosynovial giant cell tumor (TGCT).
Innovation Solution
Development of a highly pure compound represented by Formula (I) or its hydrate, essentially free of certain impurities and formulated with pharmaceutically acceptable carriers, to selectively target CSF-1R for treating conditions like TGCT and various cancers.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If small-molecule CSF-1R inhibitors are used, then therapeutic efficacy is improved, but off-target toxicity increases due to inhibition of related kinases (KIT, PDGFRα/β, FLT3)
Solution Approach 1:
The patent applies local quality by designing a small-molecule inhibitor with specific structural features (Formula I) that create selective binding affinity for CSF-1R over related kinases. The molecular structure incorporates specific substituents and scaffolds that match the CSF-1R binding pocket geometry, enabling selective inhibition while sparing KIT, PDGFRα/β, and FLT3 from off-target effects.
Solution Approach 2:
The patent employs parameter changes by optimizing molecular properties such as binding affinity (Ki values), selectivity ratios, and pharmacokinetic parameters. The compound demonstrates selective inhibition with specific Ki values for CSF-1R versus related kinases, and the formulation optimizes plasma concentration profiles to maintain selective target engagement while minimizing off-target exposure.
2Reliability
If antibodies targeting CSF-1R are used, then specificity is improved, but plasma levels of CSF-1 increase >10,000-fold due to blockade of CSF-1 clearance
Solution Approach 1:
The patent extracts the beneficial specificity of antibody-based approaches while eliminating the harmful ligand accumulation effect. Instead of using antibodies that block CSF-1 binding and clearance, the small-molecule inhibitor (Formula I) directly inhibits the CSF-1R kinase domain, bypassing the need for CSF-1 binding and avoiding the clearance blockade that causes >10,000-fold plasma CSF-1 increases.
Solution Approach 2:
The small-molecule inhibitor acts as an intermediary that achieves CSF-1R inhibition through a different mechanism than antibodies. Rather than blocking the CSF-1/CSF-1R interaction interface, the small molecule binds to the kinase domain and inhibits catalytic activity, serving as a mediator that decouples target inhibition from ligand clearance blockade.
3Ease of manufacture
If impurities are present in the pharmaceutical composition, then manufacturing cost is reduced, but stability and shelf life are compromised
Solution Approach 1:
The patent applies parameter changes by establishing specific purity thresholds and impurity limits for the pharmaceutical composition. The formulation specifies acceptable ranges for impurity levels that balance manufacturing feasibility with stability requirements, defining quantitative parameters for quality control that ensure adequate shelf life and compositional stability.
Data Source
AI summary
Provided herein, in part, is a compound of Formula (I)or a hydrate thereof,essentially free of one or more impurities, compositions thereof, and methods of use thereof.